IL-22 inhibitors to treat inflammatory disorders such as arthritis

Abstract

IL-22 is a recently described cytokine showing 23% amino acid identity with IL-10, and which has been previously shown to induce the production of acute phase proteins in liver and pancreas, suggesting a role in inflammatory responses. This patent application claims agents that modulate IL-22 activity useful as modulators of a large panel of inflammatory disorders, including autoimmune diseases, cancer and sepsis. More particularly, anti-IL-22 antibodies are reported to inhibit arthritis in a mouse model.

• cytokines
• IL-22
• inflammation
• rheumatoid arthritis